Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates

Abstract

Histone deacetylases (HDAC) are involved in the regulation of gene transcription. Aberrant HDAC activity has been associated with tumorigenesis, and, therefore, HDACs are potential targets for the treatment of cancers, including tumors of the central nervous system (CNS). Belinostat is a novel, potent, pan-HDAC inhibitor with antiproliferative activity on a… (More)
DOI: 10.1007/s00280-007-0622-5

Topics

4 Figures and Tables

Cite this paper

@article{Warren2007PlasmaAC, title={Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates}, author={Katherine E. Warren and Cindy L. McCully and Henrik K Dvinge and Jette Tj\ornelund and Maxwell Sehested and Henri S. Lichenstein and Frank M Balis}, journal={Cancer Chemotherapy and Pharmacology}, year={2007}, volume={62}, pages={433-437} }